Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Alexi A. Wright
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial
Abstract Immune checkpoint inhibitors (ICI) synergize preclinically with antibody drug conjugates (ADC), harboring anti-tubulin maytansinoid payloads. We conducted an investigator-initiated, single-arm, phase 2 trial of mirvetuximab soravtansine (MIRV), a folate receptor alpha (FOLR1/FRα)-targeting ADC with the maytansinoid payload, DM4, combined with pembrolizumab in female patients with recurrent FOLR1-expressing serous endometrial cancer (EC, NCT03835819).
A Scalable Model to Improve Cancer Care for Older Adults
Individuals aged 70 years and older account for more than 40% of patients with cancer in the US and 25% of those with incident cancers.1 Yet older adults have been largely neglected by cancer research and care improvement efforts. Less than 3% of older patients with cancer are enrolled in oncology clinical trials,2,3 and the landscape of treatments received by older adults is not well understood.
Oncologists’ role in end‐of‐life chemotherapy and patient‐centered care
Corresponding Author Christopher Manz MD, MSHP Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA Correspondence Christopher Manz, 450 Brookline Ave, Dana 1111, Boston, MA 02215, USA. Email: Christopher_Manz@dfci.harvard.edu Search for more papers by this author
Quality of Life and Endometrial Cancer Survivorship
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A. Matulonis, MD: Hello. I'm Dr Ursula Matulonis, and welcome to season 1 of the Medscape InDiscussion Endometrial Cancer podcast series.
Organization of Cancer Specialists in US Physician Practices and Health Systems
Abstract To describe the supply of cancer specialists, the organization of cancer care within versus outside of health systems, and the distance to multispecialty cancer centers. Using the 2018 Health Systems and Provider Database from the National Bureau of Economic Research and 2018 Medicare data, we identified 46,341 unique physicians providing cancer care.
Germline BRCA testing underused for women with ovarian cancer and commercial insurance
March 09, 2022 2 min read Save Source/Disclosures Published by: Disclosures: Wright reports personal fees from GlaxoSmithKline and grants from AstraZeneca and National Comprehensive Cancer Network outside the submitted work. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request.
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
PURPOSE Uterine serous carcinoma (USC) is a distinct histologic subtype of endometrial cancer, with molecular characteristics suggesting frequent cell-cycle dysregulation paired with a high level of oncogene-driven replication stress. Adavosertib is a potent and selective oral inhibitor of the WEE1 kinase, a key regulator of the G2/M and S phase cell-cycle checkpoints.
Cancer patients' experiences with medicinal cannabis-related care
Abstract Background Little is known about medical cannabis (MC)–related care for patients with cancer using MC. Methods Semistructured telephone interviews were conducted in a convenience sample of individuals (n = 24) with physician‐confirmed oncologic diagnoses and state/district authorization to use MC (Arizona, California, Florida, Illinois, Massachusetts, Oregon, New York, and Washington, DC) from April 2017 to March 2019.
Patterns and predictors of cancer‐related fatigue in ovarian and endometrial cancers: 1‐year longitudinal study
Original Article Hanneke Poort PhD Corresponding Author E-mail address: hanneke_poort@dfci.harvard.edu https://orcid.org/0000-0002-1196-699X Department of Psychosocial Oncology and Palliative Care, Dana‐Farber Cancer Institute, Boston, Massachusetts, USA Corresponding Author: Hanneke Poort, PhD, Department of Psychosocial Oncology and Palliative Care, Dana‐Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (E-mail address: hanneke_poort@dfci.harvard.edu).
Medical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study
Although almost every state medical marijuana (MM) law identifies cancer as a qualifying condition, little research supports MM’s use in oncology. We hypothesized that the discrepancy between these laws and the scientific evidence base poses clinical challenges for oncologists. Oncologists’ beliefs, knowledge, and practices regarding MM were examined in this study. In November 2016, we mailed a survey on MM to a nationally-representative, random sample of 400 medical oncologists.
Medical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study
Although almost every state medical marijuana (MM) law identifies cancer as a qualifying condition, little research supports MM’s use in oncology. We hypothesized that the discrepancy between these laws and the scientific evidence base poses clinical challenges for oncologists. Oncologists’ beliefs, knowledge, and practices regarding MM were examined in this study. In November 2016, we mailed a survey on MM to a nationally-representative, random sample of 400 medical oncologists.
Medical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study
Although almost every state medical marijuana (MM) law identifies cancer as a qualifying condition, little research supports MM’s use in oncology. We hypothesized that the discrepancy between these laws and the scientific evidence base poses clinical challenges for oncologists. Oncologists’ beliefs, knowledge, and practices regarding MM were examined in this study. In November 2016, we mailed a survey on MM to a nationally-representative, random sample of 400 medical oncologists.
Beyond Burnout — Redesigning Care to Restore Meaning and Sanity for Physicians | NEJM
In late 2016, a primary care physician with a thriving practice decided it was time to shut her doors. She felt her retirement was forced on her after she’d spent a year in the grips of her health care system’s new electronic health record (EHR). It was her fourth EHR over her years of doctoring, but this transition felt different.
Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study
Objective To estimate the causal effect of increased use of neoadjuvant chemotherapy (NACT) on all cause mortality in advanced epithelial ovarian cancer. Setting Cancer programs throughout the United States accredited by the Commission on Cancer.
The Relationship of Obesity to Hospice Use and Expenditures
John A. Harris, MD, MSc; Chithra R. Perumalswami, MD, MSc; Kenneth M. Langa, MD, PhD; Alexi A. Wright, MD, MPH; Jennifer J. Griggs, MD, MPH John A. Harris, MD, MSc From University of Pittsburgh and Magee-Womens Research Institute, Pittsburgh, Pennsylvania; University of Michigan, Ann Arbor, Michigan; and Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts. Chithra R.
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.
Family Perspectives on Aggressive Cancer Care Near the End of Life
Importance Patients with advanced-stage cancer are receiving increasingly aggressive medical care near death, despite growing concerns that this reflects poor-quality care. Objective To assess the association of aggressive end-of-life care with bereaved family members’ perceptions of the quality of end-of-life care and patients’ goal attainment.
Trends in Advance Care Planning in Patients With Cancer: Results From a National Longitudinal Survey
Importance Advance care planning (ACP) may prevent end-of-life (EOL) care that is nonbeneficial and discordant with patient wishes. Despite long-standing recognition of the merits of ACP in oncology, it is unclear whether participation in ACP by patients with cancer has increased over time.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Alexi A.
Contact Alexi A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack